F.D.A. Orders Genetic Testing Firm to Stop Selling DNA Analysis Service

23andMe, Inc. 11/22/13

Department of Health and Human Services	Public Health Service Food and Drug Administration
	10903 New Hampshire Avenue Silver Spring, MD 20993

Nov 22, 2013

Ann Wojcicki

CEO

23andMe, Inc.

1390 Shoreline Way

Mountain View, CA 94043

 

Document Number: GEN1300666

Re: Personal Genome Service (PGS)

 

WARNING LETTER

 

Dear Ms. Wojcicki,

 

The Food and Drug Administration (FDA) is sending you this letter because you are marketing the 23andMe Saliva Collection Kit and Personal Genome Service (PGS) without marketing clearance or approval in violation of the Federal Food, Drug and Cosmetic Act (the FD&C Act). 

 

This product is a device within the meaning of section 201(h) of the FD&C Act, 21 U.S.C. 321(h), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or function of the body. For example, your company’s website at www.23andme.com/health (most recently viewed on November 6, 2013) markets the PGS for providing “health reports on 254 diseases and conditions,” including categories such as “carrier status,” “health risks,” and “drug response,” and specifically as a “first step in prevention” that enables users to “take steps toward mitigating serious diseases” such as diabetes, coronary heart disease, and breast cancer. Most of the intended uses for PGS listed on your website, a list that has grown over time, are medical device uses under section 201(h) of the FD&C Act. Most of these uses have not been classified and thus require premarket approval or de novo classification, as FDA has explained to you on numerous occasions.

 

Some of the uses for which PGS is intended are particularly concerning, such as assessments for BRCA-related genetic risk and drug responses (e.g., warfarin sensitivity, clopidogrel response, and 5-fluorouracil toxicity) because of the potential health consequences that could result from false positive or false negative assessments for high-risk indications such as these. For instance, if the BRCA-related risk assessment for breast or ovarian cancer reports a false positive, it could lead a patient to undergo prophylactic surgery, chemoprevention, intensive screening, or other morbidity-inducing actions, while a false negative could result in a failure to recognize an actual risk that may exist. Assessments for drug responses carry the risks that patients relying on such tests may begin to self-manage their treatments through dose changes or even abandon certain therapies depending on the outcome of the assessment. For example, false genotype results for your warfarin drug response test could have significant unreasonable risk of illness, injury, or death to the patient due to thrombosis or bleeding events that occur from treatment with a drug at a dose that does not provide the appropriately calibrated anticoagulant effect. These risks are typically mitigated by International Normalized Ratio (INR) management under a physician’s care. The risk of serious injury or death is known to be high when patients are either non-compliant or not properly dosed; combined with the risk that a direct-to-consumer test result may be used by a patient to self-manage, serious concerns are raised if test results are not adequately understood by patients or if incorrect test results are reported.

...  MORE

NYTimes Article

Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease

Beta-amyloid plaque accumulation, glucose hypometabolism, and neuronal atrophy are hallmarks of Alzheimer’s disease. However, the regional ordering of these biomarkers prior to dementia remains untested. In a cohort with Alzheimer’s disease mutations, we performed an integrated whole-brain analysis of three major imaging techniques: amyloid PET, [18F]fluro-deoxyglucose PET, and structural MRI. We found that most gray-matter structures with amyloid plaques later have hypometabolism followed by atrophy. Critically, however, not all regions lose metabolic function, and not all regions atrophy, even when there is significant amyloid deposition. These regional disparities have important implications for clinical trials of disease-modifying therapies.

more

Graphene: The quest for supercarbon

Graphene's dazzling properties promise a technological revolution, but Europe may have to spend a billion euros to overcome some fundamental problems.

Graphene offers a way to make flexible and transparent smartphone screens.

BYUNG HEE HONG

Mr G gazes out from a recruitment poster hanging in an engineering building in Cambridge, UK. His cartoon cape billows out behind him, his sketched-in muscles ripple beneath his costume, his chest is emblazoned with a 'G' inside a hexagon — and his forefinger points straight at the viewer. “I want you for the Graphene Flagship!” declares the cartoon crusader, championing a material as super as he is.

Graphene is the thinnest substance ever made: a single sheet of carbon atoms arranged in a hexagonal honeycomb pattern. It is as stiff as diamond and hundreds of times stronger than steel — yet at the same time is extremely flexible, even stretchable. It conducts electricity faster at room temperature than any other known material, and it can convert light of any wavelength into a current. In the decade since graphene was first isolated, researchers have proposed dozens of potential applications, from faster computer chips and flexible touchscreens to hyper-efficient solar cells and desalination membranes

Hence Mr G's call to arms. The character was created in 2011 to help publicize a multinational push for a Graphene Flagship project: a decade-long, €1-billion (US$1.35-billion), all-European effort to take graphene from the laboratory bench to the factory floor

Most research laboratories still make graphene using the method pioneered in 2004 by Andre Geim and Konstantin Novoselov at the University of Manchester, UK, who went on to win the 2010 Nobel Prize in Physics for their studies. Geim and Novoselov found that they just had to touch a strip of household sticky tape to ordinary graphite — which consists of billions of layers of graphene stacked on top of one another — and they could peel off thin flakes of carbon. By repeatedly splitting those flakes, they were eventually left with graphene². This was a technique that any laboratory could use, and graphene research exploded.

But the method is much too slow and finicky for industrial-scale production. Just one micrometre-sized flake made in this way can cost more than $1,000 — making it, gram for gram, one of the most expensive materials on Earth.

The leading alternative³ relies on chemical vapour deposition (CVD), whereby methane is piped over a catalytic copper foil heated to about 1,000 °C. As the methane breaks down, small islands of pure carbon begin to grow on the foil, linking together to form a patchwork polycrystalline sheet of graphene. Harsh chemicals are then used to etch away the copper to free a sheet of graphene tens of centimetres wide, which can be transferred to a silica or polymer substrate. That process brings costs below $100,000 per square metre, but the product is often riddled with defects, impairing its electrical properties and making it much weaker than flakes produced by the sticky-tape method.

more

HPV: Sex, cancer and a virus

Human papillomavirus is causing a new form of head and neck cancer— leaving researchers scrambling to understand risk factors, tests and treatments.

Human papillomavirus, seen in a coloured transmission electron micrograph.

PASIEKA/SPL/GETTY

On a sunny day in 1998, Maura Gillison was walking across the campus of Johns Hopkins University in Baltimore, Maryland, thinking about a virus. The young oncologist bumped into the director of the university's cancer centre, who asked politely about her work. Gillison described her discovery of early evidence that human papillomavirus (HPV) — a ubiquitous pathogen that infects nearly every human at some point in their lives — could be causing tens of thousands of cases of throat cancer each year in the United States. The senior doctor stared down at Gillison, not saying a word. “That was the first clue that what I was doing was interesting to others and had potential significance,” recalls Gillison. 

Only in 2005 did Gillison finally sit down with a doctoral student to analyse the data. Within an hour, the fruits of those years of labour popped up on the computer screen: people with head and neck cancer were 15 times more likely to be infected with HPV in their mouths or throats than those without¹. The association backed up some of Gillison's earlier work, which showed² how HPV DNA integrates itself into the nuclei of throat cells and produces cancer-causing proteins. Gillison leapt from her chair and began jumping up and down. “The association was so incredibly strong, it made me realize this was absolutely irrefutable evidence,” she says.

Since then, she and a network of other researchers have amassed a mountain of evidence that HPV causes a large proportion of head and neck cancers, and that these HPV-positive cancers are on the rise. The finding has been “a paradigm-shifting realization in the field”, says Robert Ferris, chief of the division of head and neck surgery at the University of Pittsburgh Cancer Institute in Pennsylvania.

more

Nut Consumption and Mortality

NEJM QUICK TAKE

Nut Consumption and Mortality

New research on nut consumption and mortality is summarized in a short animation.

ORIGINAL ARTICLE

Vitamin D–Binding Protein and Vitamin D Status of Black Americans and White Americans

NEJM

 Large

Large

CONCLUSIONS

Community-dwelling black Americans, as compared with whites, had low levels of total 25-hydroxyvitamin D and vitamin D–binding protein, resulting in similar concentrations of estimated bioavailable 25-hydroxyvitamin D. Racial differences in the prevalence of common genetic polymorphisms provide a likely explanation for this observation. (Funded by the National Institute on Aging and others.)

More

Risk Calculator for Cholesterol Appears Flawed

By GINA KOLATA

Published: November 17, 2013 721 Comments

Last week, the nation’s leading heart organizations released a sweeping new set of guidelines for lowering cholesterol, along with an online calculator meant to help doctors assess risks and treatment options. But, in a major embarrassment to the health groups, the calculator appears to greatly overestimate risk, so much so that it could mistakenly suggest that millions more people are candidates for statin drugs.

Mark Graham for The New York Times

Dr. Nancy Cook and Dr. Paul M. Ridker of Harvard Medical School found that a new online calculator used to assess heart treatment options overestimated the risks that many people face.

Multimedia

Graphic

Estimating Risk

“It’s stunning,” said the cardiologist, Dr. Steven Nissen, chief of cardiovascular medicine at the Cleveland Clinic. “We need a pause to further evaluate this approach before it is implemented on a widespread basis.”

The controversy set off turmoil at the annual meeting of the American Heart Association, which started this weekend in Dallas. After an emergency session on Saturday night, the two organizations that published the guidelines — the American Heart Association and the American College of Cardiology — said that while the calculator was not perfect, it was a major step forward, and that the guidelines already say patients and doctors should discuss treatment options rather than blindly follow a calculator.

more

figure
risk calculator

cartoon

November 17, 2013